Literature DB >> 17075871

Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients.

Vincent Hupertan1, Morgan Roupret, Jean-Francois Poisson, Yves Chretien, Bertrand Dufour, Nicolas Thiounn, Arnaud Mejean.   

Abstract

BACKGROUND: The aim of the current study was to establish the predictive accuracy of the Kattan postoperative nomogram for nonmetastatic renal cell carcinoma (RCC) by comparing predictions with actual disease recurrence in patients who underwent surgery in a single center in France.
METHODS: Between 1985 and 2000, 844 patients were treated for RCC. The following data were collated: age, symptoms, histology, tumor size, grade, TNM 1997 stage, recurrence, and progression. For each patient a prognostic score (predicted probability) for recurrence-free survival (RFS) at 5 years was calculated using the Kattan nomogram. The discriminating ability of the model was assessed by Harrell's concordance index (c-index). Bootstrapping was used to assess confidence intervals. Furthermore, survival was then estimated by the Kaplan-Meier method and Cox proportional hazards regression analysis.
RESULTS: In all, 565 patients (median age, 62 years) were included. At the time of the last follow-up, 81 patients had died and 101 had experienced RCC recurrence. The c-index for RFS (Kattan nomogram) was only 0.607 (95% confidence interval [CI]: 0.576-0.635). The 5-year RFS rate and cancer-specific survival rate were 81.5% and 84.7%, respectively. Of the 4 variables included in the nomogram, only TNM stage was associated with recurrence in a multivariate analysis (Cox analysis) (P = .022).
CONCLUSIONS: There was a discrepancy between predicted RFS as estimated by the Kattan nomogram and the likelihood of being recurrence-free at 5 years according to the Cox analysis in the current population of patients. However, until new dynamic models become available clinicians may still improve their predictive ability by using the current nomogram. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 17075871     DOI: 10.1002/cncr.22313

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 2.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

3.  Chest X-ray in the follow-up of renal cell carcinoma.

Authors:  B H J Doornweerd; I J de Jong; L M Bergman; H J K Ananias
Journal:  World J Urol       Date:  2013-10-06       Impact factor: 4.226

4.  Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Authors:  Fabio A B Schutz; Mark M Pomerantz; Kathryn P Gray; Michael B Atkins; Jonathan E Rosenberg; Michelle S Hirsch; David F McDermott; Megan E Lampron; Gwo-Shu Mary Lee; Sabina Signoretti; Philip W Kantoff; Matthew L Freedman; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2012-12-07       Impact factor: 41.316

5.  Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Alessandro Di Rosa; Vincenzo Favilla; Eugenia Fragalà; Tommaso Castelli; Salvatore Privitera; Sebastiano Cimino; Giuseppe Morgia
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 6.  Risk stratification and prognostication of renal cell carcinoma.

Authors:  Vincenzo Ficarra; Antonio Galfano; Giacomo Novara; Massimo Iafrate; Matteo Brunelli; Silvia Secco; Stefano Cavalleri; Guido Martignoni; Walter Artibani
Journal:  World J Urol       Date:  2008-04-08       Impact factor: 4.226

7.  Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Irina Ostrovnaya; Anders Jacobsen; Katalin Susztak; Jonathan A Coleman; Paul Russo; Andrew G Winer; Roy Mano; Alexander I Sankin; Robert J Motzer; Martin H Voss; Kenneth Offit; Mark Purdue; Mark Pomerantz; Matthew Freedman; Toni K Choueiri; James J Hsieh; Robert J Klein
Journal:  Cancer       Date:  2015-10-27       Impact factor: 6.860

8.  Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram.

Authors:  D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

9.  Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.

Authors:  A Kapoor; A Gharajeh; A Sheikh; J Pinthus
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

10.  Prognostic factors of overall survival in renal cancer patients - single oncological center study.

Authors:  Tomasz Drewniak; Marek Sandheim; Jacek Jakubowski; Kajetan Juszczak; Andrzej Wojciech Stelmach
Journal:  Cent European J Urol       Date:  2013-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.